The cost of publication in Journal of Biomedical Science is borne by the National Science Council, Taiwan.
Research
TGF-β inhibits IL-1β-activated PAR-2 expression through multiple pathways in human primary synovial cells
-
* Corresponding author: Chien-Ho Chen chenchho@tmu.edu.tw
- † Equal contributors
1 Department of Neurosurgery, Department of Emergency and Critical Care Medicine, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan, Republic of China
2 Graduate Institute of Pharmaceutical Sciences, Taipei Medical University, Taipei, Taiwan, Republic of China
3 School of Medical Laboratory Science & Biotechnology, Taipei Medical University, Taipei, Taiwan, Republic of China
4 Department of Laboratory Medicine, Taipei Medical University Hospital, Taipei, Taiwan, Republic of China
Journal of Biomedical Science 2009, 16:97 doi:10.1186/1423-0127-16-97
Published: 23 October 2009Abstract
To investigate the mechanism how Transforming growth factor-β(TGF-β) represses Interleukin-1β (IL-1β)-induced Proteinase-Activated Receptor-2 (PAR-2) expression in human primary synovial cells (hPSCs). Human chondrocytes and hPSCs isolated from cartilages and synovium of Osteoarthritis (OA) patients were cultured with 10% fetal bovine serum media or serum free media before treatment with IL-1β, TGF-β1, or Connective tissue growth factor (CTGF). The expression of PAR-2 was detected using reverse transcriptase-polymerase chain reaction (RT-PCR) and western blotting. Collagen zymography was performed to assess the activity of Matrix metalloproteinases-13 (MMP-13). It was demonstrated that IL-1β induces PAR-2 expression via p38 pathway in hPSCs. This induction can be repressed by TGF-β and was observed to persist for at least 48 hrs, suggesting that TGF-β inhibits PAR-2 expression through multiple pathways. First of all, TGF-β was able to inhibit PAR-2 activity by inhibiting IL-1β-induced p38 signal transduction and secondly the inhibition was also indirectly due to MMP-13 inactivation. Finally, TGF-β was able to induce CTGF, and in turn CTGF represses PAR-2 expression by inhibiting IL-1β-induced phospho-p38 level. TGF-β could prevent OA from progression with the anabolic ability to induce CTGF production to maintain extracellular matrix (ECM) integrity and to down regulate PAR-2 expression, and the anti-catabolic ability to induce Tissue inhibitors of metalloproteinase-3 (TIMP-3) production to inhibit MMPs leading to avoid PAR-2 over-expression. Because IL-1β-induced PAR-2 expressed in hPSCs might play a significantly important role in early phase of OA, PAR-2 repression by exogenous TGF-β or other agents might be an ideal therapeutic target to prevent OA from progression.